id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S17127 R71767 |
Delteil - Beta-blockers, 2024 | Intrauterine deaths (early, late and therapeutic) | at least 1st trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Indications Antihypertensive: Only chronic indication (hypertension or cardiac) | 2.07 [1.61;2.66] | 62/823 10,077/161,052 | 10,139 | 823 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S14051 R55683 |
Xiang - Labetalol, 2020 | Intrauterine fetal demise (NOS) | during pregnancy (anytime or not specified) | randomized controlled trial | unexposed, sick | Adjustment: Randomisation Indications Antihypertensive: Only chronic hypertension indication | 0.59 [0.14;2.50] C | 3/127 5/126 | 8 | 127 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 2 studies | 1.36 [0.42;4.37] | 10,147 | 950 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded